Vaccine Management Update March 2024
This email will cover the following topics:
  • 2024 Annual Enrollment Update
  • 2023-2024 Influenza Vaccine Supply
  • Nirsevimab Ordering Update
  • COVID-19 Ordering Update
  • Pfizer COVID 6m-4y Diluent Update
  • Friendly Reminders
2024 Annual Re-Enrollment Update
The 2024 Annual Re-Enrollment Period for the State Vaccine Program is now officially closed as of March 1, 2024. Please ensure that your site has submitted your re-enrollment request and that the request has been approved by the Vaccine Management Unit. If your site was initially rejected due to missing items, please resolve those issues as soon as possible and re-submit the re-enrollment request in the MIIS. Site re-enrollment submissions are processed in the order they are submitted. If not done so already, please submit your re-enrollment request in the MIIS as soon as possible, to ensure ample time for your submission to be reviewed and processed by the Vaccine Management Unit.

All sites that have not completed their 2024 Annual Re-Enrollment have been switched to a "Past Re-Enrollment" status. Sites in a "Past Re-Enrollment" status will not be able to place orders or input transfers, until their re-enrollment is complete. The final deadline to complete the 2024 Annual Re-Enrollment process is March 29, 2024. Sites that remain in a "Past Re-Enrollment" status as of March 29 will be switched to "Left Program" and will need to complete the entirety of the enrollment process to once again join the program.

As a reminder, all site types (including Flu/COVID-Only and Adult-Only providers) are required to submit a completed 2024 version of both the Vaccine Management SOP and Vaccine Transport SOP as part of the re-enrollment process. These documents must be uploaded on the Agreement to Comply tab of your site's MIIS enrollment profile.
2023-2024 Influenza Vaccine Supply
Refer to the table below, for which Flu vaccine formulations are available to order in the MIIS. Flucelvax (NDC: 70461-0323-03) and FluMist (NDC: 66019-0310-10) are no longer available to order. If a Flucelvax is needed for a patient with an egg allergy, please contact the vaccine unit.
Important Reminders:
  • Account for state-supplied flu vaccines by reporting data directly to the MIIS registry. It is a requirement that all vaccinations must be reported into the MIIS within 3 days of administration to the patient.
  • Submit flu vaccine orders as frequently as needed to meet the needs of your practice population.
  • Sites are able to order above their listed ceiling limits in the MIIS.
  • Flu ordering is not yet opened for the 2024-2025 Flu Season. All flu vaccines being shipped out currently, will expire at the end of June 2024. Flu ordering for the 2024-2025 Flu Season will open in August of 2024.
Nirsevimab Ordering Update
Earlier this season, in the context of limited supply at the time, CDC provided interim guidance for prioritization of nirsevimab administration. However, current CDC guidance advises healthcare providers to return to the recommendations issued by CDC/ACIP guiding the use of nirsevimab in young children if supplies allow.

As a reminder, nirsevimab ordering is turned off in the MIIS and MDPH is not expecting any more doses to be allocated to us from the CDC or manufacturer. However, we do know that there still are available doses in many providers’ inventories. If your site has excess nirsevimab 50mg or 100mg doses in inventory, that will not be able to be administered this RSV season, please contact the Vaccine Management Unit for assistance moving those doses to another provider that will be able to utilize them.

Do not split or double doses to get to the correct dosage size. Providers should not vaccinate a baby over 5 kg with two doses of the 50 mg nirsevimab, to equal the 100 mg dose of nirsevimab or vaccinate a baby under 5kg with a half dose of the 100 mg nirsevimab product.
Pfizer COVID 6m-4y Diluent Update
Pfizer has updated the diluent package size associated with all orders of the 2023-2024 formulation of Pfizer 6m-4y COVID-19 Vaccine (NDC: 59267-4315-02). Pfizer will now supply diluent in a 25 pack with vaccine shipments.

Please refer to the table below that illustrates the number of diluent vials providers will receive based on order sizes ranging from 30 to 120 doses of Pfizer 6m-4y. For vaccine orders larger than 120 doses of Pfizer 6m-4y, additional diluent will be included. 
COVID-19 Ordering Update
Refer to the table below, for which COVID-19 vaccine formulations are available to order in the MIIS.
***All sites that receive VFC vaccines are required to have COVID vaccines in their inventory to offer to patients. If your site has not ordered Pediatric COVID vaccine, please do so immediately to stay in compliance with programmatic requirements. ***

Sites are required to keep all packing slips for vaccine shipments, including Pfizer COVID-19 vaccine shipments (Pfizer 6m-4y, Pfizer 5y-11y and COMIRNATY +12y). Pfizer packing slips are currently appearing as stickers on the inside flap of the shipment container. To stay in compliance with programmatic guidelines, please take picture of the packing slip sticker and save the picture in your records (either digitally or a print out). Packing slips are not required to be sent to the Vaccine Management Unit for Moderna vaccine orders, but they must be kept on file at your site.
Friendly Reminders
  • Daylight Savings Time will occur on March 10th this year. Please ensure your site adjusts the time appropriately on all data logger devices.
  • Always include PIN/Site Number, name and phone number when contacting the Vaccine Management Unit.
  • The Vaccine Storage Labels for routinely recommended vaccines are now live on the CDC website. These include new vaccines such as Mpox and RSV.
  • Upload temperature logs monthly in the MIIS. If temperature log data is missing (loggers hold 56 days), the Vaccine Management Unit cannot be confident that temperatures have remained in-range and this may result in loss of vaccine and possible restitution.
  • If your site experiences a temperature excursion involving TD vaccine from Mass Biologics, email the manufacturer at regulatoryaffairs@massbiologics.org for vaccine viability.
Vaccine Management Unit
P: 617-983-6828 | F: 617-983-6924